BPMC (Common Stock) $79.24 Stock is Up 0.91 (1.16%)
    04/26/18 4:00 p.m. ET
    Data provided by Nasdaq. Minimum 15
    minutes delay
    Refresh quote

    Corporate Profile

    Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.Read More

    Upcoming Events

    Q1 2018 Blueprint Medicines Corp Earnings Conference Call
    Wednesday, May 2, 2018 8:30 a.m. ET

    View More


    Blueprint Medicines – Investor Presentation (January 2018)

    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet